

SEP 10 2008

PATENT

Rev 02/07

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application : Laszlo Takacs et al.  
Application No. : 10/588,392  
Filed : August 03, 2006  
Confirmation No. : 8285  
For : MONOCLONAL ANTIBODY BASED BIOMARKER  
DISCOVERY AND DEVELOPMENT PLATFORM  
Examiner : Jeffrey S. Lundgren  
Attorney's Docket : NU-BI-659XX

TC Art Unit: 1639

\*\*\*\*\*  
I hereby certify that this correspondence is being sent via  
facsimile to Examiner Jeffrey S. Lundgren, TC Art Unit 1639, Fax  
No. (571) 273 8300, on Sept. 10, 2008.

By: Holliday C. Heine  
Holliday C. Heine, Ph.D.  
Registration No. 34,346  
Attorney for Applicant(s)

\*\*\*\*\*

RESPONSE TO RESTRICTION REQUIREMENT

Via Facsimile  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Restriction Requirement dated August 11,  
2008, Applicants hereby elect Group I, with traverse, for  
prosecution at this time. The species elected for search purposes  
are:

Attorney Docket No. NU-BI-659XX  
WEINGARTEN, SCHURGIN,  
GAGNEBIN & LEBOVICI LLP  
TEL. (617) 542-2290  
FAX. (617) 491-0313

Application No. 10/588,392  
Filed: August 03, 2006  
TC Art Unit: 1639  
Confirmation No.: 8285

- A. the *selecting step* - claim 2
- B. the *pretreatment* of the analyte - claim 5
- C. the *complex analyte* - claim 6
- D. the *origin* of the complex analyte - claim 18

Traverse is on the grounds that there would be no undue effort for the Examiner to search the one claim in Group II.